Mechanism of ETI Therapy on NLRP3 Inflammasome in Cystic Fibrosis
發布者：Unknown
·發布於：2025-12-14
Discussion regarding how elexacaftor/tezacaftor/ivacaftor (ETI) therapy functions to downregulate the NLRP3 inflammasome pathway and subsequently reduce pro-inflammatory cytokine production in the context of cystic fibrosis.
載入中...